진양곤의 승부수: 10억 원의 책임경영이 던지는 메시지와 신약 허가의 갈림길 > K-wave Trends

The core of Chairman Jin Yang-gon's recent move is that it involved 1 billion won in open-market purchases made over just a few days in early June. He engaged in comprehensive stake acquisition across major subsidiaries, including HLB Genex, HLB Innovation, HLB Therapeutics, HLB Biostep, and HLB Panagene. This purchase, with the largest portion allocated to HLB Genex, proves the owner's trust in the key subsidiaries leading the group's new drug development. It is read strongly as a demonstration of his will to show through action that the company's mid-to-long-term value has not been damaged, despite market volatility, rather than a temporary measure aimed at boosting stock prices. It is being evaluated as a strategic move to imprint a management philosophy that remains unshaken even in times of crisis upon investors.

Behind this stake purchase lie significant new drug approval events lined up for the second half of this year. In July, the US FDA is scheduled to decide on the approval of the liver cancer treatment using the combination therapy of Rivoceranib and Camrelizumab, and in September, the review results for the bile duct cancer treatment candidate, Lirafugratinib, will be released. Furthermore, with the announcement of global Phase 3 clinical data for HLB Therapeutics' neurotrophic keratitis treatment 'RGN-259' approaching, the group stands at a critical juncture that will determine its entire fate. By increasing his stake personally ahead of these major momentum events, Chairman Jin is indirectly conveying his confidence in clinical success to the market.

Along with the stake purchase, another point to note is the "relay corporate presentation (IR)" that Chairman Jin is conducting himself. Since last month, he has been touring major domestic brokerage branches to personally brief private bankers (PBs) and high-net-worth individuals on the group's core pipeline and growth vision. This move reflects the owner's strong dissatisfaction that the current stock price does not sufficiently reflect the company's potential, as well as his determination to restore investment sentiment through direct communication. His "field management," aimed at resolving market information asymmetry and broadening touchpoints with investors to form favorable public opinion, is interpreted as an attempt to build trust that goes beyond mere numerical stock prices.

However, there is a complex shadow behind this aggressive responsible management. Recently, the sale schedule of stock warrants during HLB Pharmaceutical's paid-in capital increase became controversial as it coincided with the FDA approval status, which is a point of concern for the market. As the structure was designed so that the value of the warrants would differ drastically depending on the new drug approval, criticism arose that the interests of the controlling shareholder and minority shareholders could collide. Following this, the Financial Supervisory Service issued a request for correction, and HLB has stepped back, stating it would re-examine the schedule and structure of the capital increase with priority on investor protection. This shows that, separate from the owner's will for responsible management, the transparency of corporate governance to protect shareholder value remains a critical task.

Ultimately, Chairman Jin Yang-gon's recent move can be seen as a sophisticated political gamble to catch two rabbits: the "essence of new drug development" and "communication with the market." Given the nature of bio companies, where the success of R&D determines the entire corporate value, the owner personally injecting capital is the most certain signal that can be sent to the market. However, in a situation where the uncertainty of new drug development persists, how much this confidence can resolve market concerns depends on the FDA's final decision in the second half of the year. Depending on the outcome, Chairman Jin's stake purchase stands at a crossroads where it could be recorded as "farsighted investment" or remain as a "limitation of crisis management."